VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

Boryung Pharmaceutical Co., Ltd203 enrolled

Overview

The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-naïve patients with multiple myeloma who are ineligible for hematopoietic transplantation. Despite the fact that VMP therapy is outstanding in terms of cost-effectiveness, treatment discontinuation rates due to adverse drug reactions is high. In addition, when considering that the percentage of elderly patients aged 70 years or above in the target patient group is 20% or above, there have been attempts to devise a plan that can decrease side effects while maintaining effectiveness. For example, there have been previous reported cases of overseas applications of modified VMP therapies with reduced doses, but they have applied various combinations in terms of the total cycles, administration intervals, doses, etc. This study was planned to evaluate the overall safety and efficacy of VMP therapy by following up on the actual VMP therapies applied in domestic clinics, patient characteristics, side effect occurrences, administration discontinuation rates, survival data, etc., as well as to collect exploratory data for a more effective study of modified VMP therapies. This study was planned to evaluate the overall safety and efficacy of VMP therapy by following up on the actual VMP therapies applied in domestic clinics, patient characteristics, side effect occurrences, administration discontinuation rates, survival data, etc., as well as to collect exploratory data for a more effective study of modified VMP therapies.

The data produced when subjects visit the hospital for treatment are collected in case report forms. The follow-up time specified in the following refer to the data collection time. That is, a subject's visit schedule is freely determined by the investigator based on the medical condition of the subject regardless of the follow-up time specified in this protocol, but data that are determined necessary in relation to the study among the data produced during the study period may be collected in CRFs. In regard to various tests for monitoring of treatment effects including laboratory tests, the corresponding tests are not performed separately for this clinical study, and only those items with existing test results are collected. The following data are collected in CRFs during the study period. * Demographic information of subjects * Information on multiple myeloma disease (diagnosis date, diagnosis criteria and related test results, disease stage \[ISS and revised ISS\], number of osseous lesions) * Intercurrent diseases * Height and body weight * ECOG PS * IMWG Frailty score * Laboratory results * Radiologic results * Bone marrow examination results * Supportive therapy administered for symptoms related to multiple myeloma (drug / surgery / radiotherapy) * Detailed information of administered VMP therapy * Maintenance therapy / VMP replacement therapy * Clinical response * Survival * Adverse drug reactions related to VMP therapy * Serious adverse events/adverse drug reactions

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who provide written consent on the informed consent form for use of personal information after listening to an explanation regarding the purpose, method, etc., of this clinical study * Adult males and females aged 19 years or above * Patients without previous experience of treatment for multiple myeloma who have been evaluated as ineligible for hematopoietic transplantation * Patients scheduled to receive the 3-drug combination (VMP therapy) treatment * Patients with expected survival period of 6 months or more * Patients evaluated as having performance status score (ECOG PS) ≤2 (score of 0, 1, 2) * Patients who have received the following tests within 6 months prior to enrollment * Beta2-microglobulin * Serum albumin * Serum LDH * Patients with confirmed del (17), t (4;14), t (14;16) by hybridization FISH test Exclusion Criteria: * Patients who have been newly diagnosed with other primary cancers within the last 5 years that can affect the treatment or prognosis of multiple myeloma * Pregnant women and breast-feeding women * Patients who are currently participating in other clinical studies (drug or medical device clinical studies) or planning to participate in other clinical studies during the study participation period * Patients who are determined ineligible to participate in the study by other judgments of the investigator

Locations (24)

Soonchunhyang University Bucheon hospital

Bucheon-si, South Korea

Inje university Haeundae Paik Hospital

Busan, South Korea

Kosin University Gospel hospital

Busan, South Korea

Pusan national University Hospital

Busan, South Korea

Keimyung University Hospital(Dongsan Medical Center)

Daegu, South Korea

Yeungnam University Medical Center

Daegu, South Korea

Chungnam National University Hospital

Daejeon, South Korea

National Cancer Center

Goyang, South Korea

Gyeongsang National University Changwon Hospital

Gyeongsang, South Korea

Chonnam National University Hwasun Hospital

Hwasun, South Korea

...and 14 more locations

Outcomes

Primary Outcomes

PFS (progression-free survival)

the survival rate curve of PFS and the median, as well as the 95% confidence interval for this are presented. An event is 'confirmation of progressive disease (PD)' or 'death,' and others are processed as censored at the later time point between the final follow-up time point and the time point of final clinical response evaluation.